TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04840875

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: chimeric antigen receptor T cell treatment
Description: Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: about 3 days before cells transfusion, the patients who planned to reinfuse CAR T cells were treated with fluorodarabine 30 mg/m2( body surface area) and cyclophosphamide 250 mg/m2( body surface area) for 3 days. Then this study will be using a 3+3 dose escalation approach from dose 1 (DL-1): 5×105 (±20%) to dose 2 (dl-2): 1×106 (±20%). Below the lowest dose was reinfused at the PI's discretion.
Study: NCT05077917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cromolyn Sodium
Description: Nebulized treatment for 4 days followed by intranasal treatment starting on day 5.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nebulized treatment for 4 days followed by intranasal treatment starting on day 5.
Study: NCT06449183

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VIDAS® TBI Test [GFAP and UCH-L1 assays]
Description: The VIDAS® TBI (GFAP, UCH-L1) test is composed of two automated assays - VIDAS® TBI (GFAP) and VIDAS® TBI (UCH-L1) - to be used on the VIDAS® family of instruments for the quantitative measurement of Glial 15 Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase- L1 (UCH-L1) in human serum using the Enzyme Linked Fluorescent Assay (ELFA) technique. The results of both assays are required to obtain an overall qualitative test interpretation.
Study: NCT05407753

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: Subjects receive the ketone ester at the following timepoints: 25g before ultrarun, 12.5g every 30 min during race, 25g immediately after race, 25g before sleep, 3 x 25g on day after race.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive a non-caloric taste-matched placebo (water with sucrose octaacetate)
Study: NCT06158438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-754-4 Treatment
Description: Treatment with the BTL-754 device with the BTL-754-4 applicator for reduction of facial wrinkles.
Study: NCT04763161

Intervention type: PROCEDURE
Intervention: Decompressive hemicraniectomy
Description: Decompressive hemicraniectomy in the context of a malignat sylvian ischaemic cerebral accident

Intervention type: PROCEDURE
Intervention: neurosurgical operation
Description: neurosurgical operation on which cranial, meningeal, vascular (branch of the middle meningeal artery) or cerebral bone tissue is not preserved during the surgical approach.
Study: NCT06455358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 61Cu-NODAGA-LM3
Description: Single intravenous administration of 61Cu-NODAGA-LM3 at an amount of 20 -40 μg (or 13 - 26 nmol) and an activity range of 150 MBq (±25%) followed by up to three PET/CT acquisitions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 61Cu-NODAGA-LM3
Description: Single intravenous administration of 61Cu-NODAGA-LM3 at an amount of 20 -40 μg (or 13 - 26 nmol) and an activity range of 150 MBq (±25%) followed by up to three PET/CT acquisitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Single intravenous administration of 68Ga-DOTA-TOC and PET/CT acquisitions as part of standard clinical care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator
Description: Single intravenous administration of 68Ga-DOTA-TOC and PET/CT acquisitions as part of standard clinical care.
Study: NCT06149273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep School
Description: Sleep school is a structured method for the treatment of insomnia, which is based on cognitive behavioral therapy for insomnia (CBT-I). The central element of the method is a workbook for the patients. The essential parts of the method are strengthening the patient's self-efficacy, introducing the therapeutic exercises, and supporting the continued use of the exercises. The main themes of the Sleep school are information about sleep and the factors affecting it, behavioural components of CBT-I, like restricting the time spent in bed, cognitive components of CBT-I, like constructive worrying -exercise, and the exercises that aim to calm down mind and the autonomic nervous system. The Sleep School is held by an educated nurse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Oral and written information about improving sleep habits given by an educated nurse.
Study: NCT06299150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPS e.max CAD
Description: CAD CAM Restoration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IPS e.max CAD
Description: CAD CAM Restoration
Study: NCT06341712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Participants will receive cabozantinib orally Once daily (QD) on a continuous dosing schedule for cycles of 28 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: Participants will receive BSC. BSC includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. but does not include tumor specific therapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care (BSC)
Description: Participants will receive BSC alone. BSC includes antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. but does not include tumor specific therapy.
Study: NCT05365295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DRM (Deese, Roediger et McDermott task)
Description: Eight lists of nine words are presented to the participants. Each list is heard once. Immediately afterwards, the child is asked to recall the words he or she remembers. Each child's response is then repeated one by one and the participant is asked to rate his or her confidence in the response on a five-point scale (from not at all sure to 100% sure). A 5-minute break is given in the middle of the task, after the first four lists are presented. The test takes about 20 minutes.
Study: NCT05232591

Intervention type: DIAGNOSTIC_TEST
Intervention: The teeth diagnosed with chronic apical periodontitis
Description: GCF samples will be taken from the teeth diagnosed with chronic apical periodontitis

Intervention type: DIAGNOSTIC_TEST
Intervention: The teeth diagnosed with chronic apical periodontitis
Description: GCF samples will be taken from the teeth diagnosed with chronic apical periodontitis
Study: NCT06589518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide Citrate
Description: Tenofovir alafenamide is administered once every day with 25mg PO for 48 weeks.
Study: NCT06675305

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice (James White, UK)
Description: One serving 140 mL of BJ (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 2.5 h before initiating the testing session.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acute supplementation (James White, UK)
Description: One serving 140 mL of BJ (0.04 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 2.5 h before initiating the testing session.
Study: NCT06689813

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D tablets
Description: Vitamin D supplements is thought to reduce the severity of urinary incontinence.Vitamin D supplements were given to Group A

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ispaghula husk
Description: Ispaghula husk tablets were given to Group B participants
Study: NCT05928871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 200mcg Tab
Description: 60 women: will receive preoperative 600 microgram of misoprostol ( 3 tablets ) rectally after spinal anaesthesia and urinary catheterization and postoperative placebo (3 tablets). (as per WHO dose recommendation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol Pill
Description: 60 women: will receive preoperative placebo 3 tablets and postoperative 600 microgram of misoprostol  3 tablets at operating theatre (as per WHO dose recommendation).
Study: NCT06689878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Cognitive Behavioral App
Description: A mobile cognitive behavioral therapy (CBT) app called Maya that includes modules with educational content and teaching and practice of strategies that address depression and anxiety after stroke.
Study: NCT06688877

Intervention type: DEVICE
Intervention: headphones with activated noise cancelling
Description: noise cancelling is new
Study: NCT05567666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optilume Catheter System
Description: Optilume Catheter System, which is a Dilation Drug Coated Balloon (DCB) Catheter
Study: NCT05761080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin clavulanic acid IV during hospitalization
Description: Amoxicillin clavulanic acid IV 5 days during hospitalization. Application of discharge criteria at 5 postoperative days, according to guidelines current clinic.
Study: NCT06688877

Intervention type: DEVICE
Intervention: headphones with activated noise cancelling and soft 60 bpm musc
Description: noise cancelling is new

Intervention type: DEVICE
Intervention: heart rate measurement
Description: three times (before, during and after surgery)
Study: NCT05761080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin clavulanic acid IV 3 days and PO until day 5
Description: Amoxicillin clavulanic acid IV 3 days during hospitalization and at discharge Amoxicillin clavulanic acid PO until day 5.~Application of discharge criteria at 72 postoperative hours, administering oral antibiotic therapy with a spectrum similar to that of the control group total of 5 days and sending the patient home with oral analgesia.
Study: NCT06688877

Intervention type: DEVICE
Intervention: heart rate measurement
Description: three times (before, during and after surgery)

Intervention type: DEVICE
Intervention: heart rate measurement
Description: three times (before, during and after surgery)

Intervention type: OTHER
Intervention: Questionnaire
Description: two times (before and after surgery)

Intervention type: OTHER
Intervention: Questionnaire
Description: two times (before and after surgery)

Intervention type: OTHER
Intervention: Questionnaire
Description: two times (before and after surgery)
Study: NCT05970939

Intervention type: OTHER
Intervention: Development of the Telerehabilitation Usability Questionnaire
Description: This study will be examined the development, validity, and reliability of the Telerehabilitation Usability Questionnaire in patients with MS.
Study: NCT05612750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: A trained psychologist delivers 8 sessions of low-literacy CBT (the LAMP protocol) to groups of patients who were randomized to this treatment arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: A trained psychologist delivers 8 sessions of low-literacy CBT (the LAMP protocol) to groups of patients who were randomized to this treatment arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: A trained psychologist delivers 8 sessions of low-literacy CBT (the LAMP protocol) to groups of patients who were randomized to this treatment arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: A trained psychologist delivers 8 sessions of low-literacy CBT (the LAMP protocol) to groups of patients who were randomized to this treatment arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowered Relief
Description: A certified instructor delivers 1 session of pain relief skills intervention (Empowered Relief) to groups of patients who were randomized to this treatment arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowered Relief
Description: A certified instructor delivers 1 session of pain relief skills intervention (Empowered Relief) to groups of patients who were randomized to this treatment arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowered Relief
Description: A certified instructor delivers 1 session of pain relief skills intervention (Empowered Relief) to groups of patients who were randomized to this treatment arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowered Relief
Description: A certified instructor delivers 1 session of pain relief skills intervention (Empowered Relief) to groups of patients who were randomized to this treatment arm.
Study: NCT06627478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKF-INS(G)
Description: Single subcutaneous dose of 0.5 IU/kg administered over three periods
Study: NCT06475339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30/30 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 30 minutes of work followed by 30 minutes of rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30/30 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 30 minutes of work followed by 30 minutes of rest.
Study: NCT06627478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-Lantus®
Description: Single subcutaneous dose of 0.5 IU/kg administered over three periods
Study: NCT06081101

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Injection
Description: Medication will be injected into SI joint under ultrasound guidance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Injection
Description: Medication will be injected into SI joint under ultrasound guidance
Study: NCT06627478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-Lantus®
Description: Single subcutaneous dose of 0.5 IU/kg administered over three periods
Study: NCT06475339

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 30/30 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 30 minutes of work followed by 30 minutes of rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30/30 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 30 minutes of work followed by 30 minutes of rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30/20 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 30 minutes of work followed by 20 minutes of rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30/20 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 30 minutes of work followed by 20 minutes of rest.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 30/20 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 30 minutes of work followed by 20 minutes of rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30/20 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 30 minutes of work followed by 20 minutes of rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 40/30 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 40 minutes of work followed by 30 minutes of rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 40/30 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 40 minutes of work followed by 30 minutes of rest.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 40/30 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 40 minutes of work followed by 30 minutes of rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 40/30 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 40 minutes of work followed by 30 minutes of rest.
Study: NCT06694753

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1645-eODGT8
Description: eOD-GT8 60mer is a self-assembling nanoparticle composed of 60 subunits of the engineered HIV-1 gp120 outer domain germline targeting version 8 (eOD-GT8) fused to an engineered form of a bacterial enzyme, Lumazine Synthase, through a 15-amino acid Glycine-Serine linker. eOD-GT8 60mer will be delivered using an mRNA lipid nanoparticle (LNP) platform. To be administered by intramuscular (IM) injection at doses of 10 or 30 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1645-eODGT8
Description: eOD-GT8 60mer is a self-assembling nanoparticle composed of 60 subunits of the engineered HIV-1 gp120 outer domain germline targeting version 8 (eOD-GT8) fused to an engineered form of a bacterial enzyme, Lumazine Synthase, through a 15-amino acid Glycine-Serine linker. eOD-GT8 60mer will be delivered using an mRNA lipid nanoparticle (LNP) platform. To be administered by intramuscular (IM) injection at doses of 10 or 30 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1645-CoreG28v2
Description: core-g28v2 60mer is a nanoparticle composed of 60 protein subunits of an engineered core-gp120 fused to an engineered form of a bacterial enzyme, Lumazine Synthase, through a 21-amino acid Glycine-Serine linker. Core-g28v2 60mer will be delivered using an mRNA-LNP platform. To be administered by IM injection at doses of 10 or 30 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1645-CoreG28v2
Description: core-g28v2 60mer is a nanoparticle composed of 60 protein subunits of an engineered core-gp120 fused to an engineered form of a bacterial enzyme, Lumazine Synthase, through a 21-amino acid Glycine-Serine linker. Core-g28v2 60mer will be delivered using an mRNA-LNP platform. To be administered by IM injection at doses of 10 or 30 mcg.
Study: NCT05678595

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-intensity laser therapy
Description: HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the hand wrist area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first five sessions consisted of a 100-second intermittent phase analgesic effect at 8 W and 8 J/cm2 for a total energy of 200 J. The following five sessions consisted of a continuous 11 minutes 6 second bio stimulating effect with a dosage of 3 W 80 J/cm2. Over the course of two weeks, ten treatment sessions of HILT will be given.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: high-intensity laser therapy
Description: HILT: A hot laser derived from a Nd: YAG laser has 12 W (watt) and 1064 nm characteristics. The device will administered to the hand wrist area in two steps in the HILT group: phase I and phase II. The application will made utilizing continuous circular movements in both phases I and II. The first five sessions consisted of a 100-second intermittent phase analgesic effect at 8 W and 8 J/cm2 for a total energy of 200 J. The following five sessions consisted of a continuous 11 minutes 6 second bio stimulating effect with a dosage of 3 W 80 J/cm2. Over the course of two weeks, ten treatment sessions of HILT will be given.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham high-intensity laser therapy
Description: HILT is administered as a placebo for two weeks, 5 sessions a week, for a total of 10 sessions.
Study: NCT06694753

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1645-N332GT5
Description: N332-GT5 gp151 is an HIV envelope glycoprotein gp151 trimer based on BG505 SOSIP MD39 (clade A) trimer with germline-targeting mutations added that confer the ability to bind germline precursors of BG18 class B cells. N332-GT5 gp151 will be delivered using an mRNA-LNP platform. To be administered by IM injection at doses of 10 or 30 mcg.
Study: NCT06475339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20/12 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 20 minutes of work followed by 12 minutes of rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20/12 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 20 minutes of work followed by 12 minutes of rest.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 20/12 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 20 minutes of work followed by 12 minutes of rest.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20/12 work/rest cycle
Description: Participants will walk on a treadmill while wearing a weighted backpack to a work/rest cycle of 20 minutes of work followed by 12 minutes of rest.
Study: NCT06694753

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1645-N332GT5
Description: N332-GT5 gp151 is an HIV envelope glycoprotein gp151 trimer based on BG505 SOSIP MD39 (clade A) trimer with germline-targeting mutations added that confer the ability to bind germline precursors of BG18 class B cells. N332-GT5 gp151 will be delivered using an mRNA-LNP platform. To be administered by IM injection at doses of 10 or 30 mcg.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT05678595

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham high-intensity laser therapy
Description: HILT is administered as a placebo for two weeks, 5 sessions a week, for a total of 10 sessions.